QYResearch is a leading market research publisher which pursuits high product quality with the belief that quality is the soul of business and consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience.
City of Industry, CA -- (SBWIRE) -- 08/17/2018 -- This report studies the global Drug Device Combination Products market status and forecast, categorizes the global Drug Device Combination Products market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America).
Drug devices facilitate early diagnosis and reduced treatment duration in a majority of surgical procedures. Growing demand is also a consequence of minimal pain, heightened cost efficiency, improved safety, better efficacy, rapid recovery, and reduced hospital stay rendered by these devices.
The global drug device combination product market size is expected to reach USD 176 billion by 2024. Increasing presence of regulatory healthcare authorities enforcing clearly defined protocols for premarket authorizations is anticipated to support manufacturers in gaining approvals for their products. Recently, the U.S. FDA incorporated the lean management process mapping approach to build a more cohesive, streamlined, systematic, and collaborative system for the review of the aforementioned products. Safety guidelines and recommendations issued by these authorities are presumed to increase the adoption of these products in future and boost overall growth during the forecast period.
Severe side effects and drug interactions associated with therapeutics owing to drug absorption by unintended sites in the body are anticipated to induce need for targeted therapy, thereby propelling demand for drug-device combinations. For instance, consistent administration of Levodopa results in long-term complications such as motor fluctuations, dyskinesias, severe metabolic changes, and neurotoxic effects. These aforementioned factors drive the clinical urgency to incorporate alternatives based on targeted therapy, as in case of drug-device combination products.
The major players covered in this report
Abbott Laboratories
Terumo Corporation
Stryker Corporation
Mylan N.V.
Medtronic
St.Jude Medical, Inc.
Allergan, Plc
Boston Scientific Corporation
Novartis AG
Teleflex Incorporated
C.R. Bard, Inc.
W.L.Core & Associates, Inc.
Request Sample Copy of Report@ https://www.qyresearch.com/sample-form/form/627625/global-drug-device-combination-products-sales-market
Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering
United States
Europe
China
Japan
Southeast Asia
India
Request to Buy Full Report@ https://www.qyresearch.com/settlement/pre/10932acf5bfaec7d84870d99a9b72f67,0,1
About QY Research
QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), expert's resources (included energy automotive chemical medical ICT consumer goods etc.